Form 4: Thermo Fisher Scientific Executive Acquires Shares and Stock Options
SEC Form 4 Filing
Lisa P. Britt, Sr. VP and Chief HR Officer of Thermo Fisher Scientific, reports acquisition of common stock and stock options.
Summary
- Lisa P. Britt, a Senior Vice President and Chief HR Officer at Thermo Fisher Scientific, filed a Form 4 detailing changes in beneficial ownership.
- On February 19, 2025, Ms. Britt acquired 871 shares of common stock at $0 and 2,611 shares of common stock at $0.
- Following these transactions, Ms. Britt directly owns 16,815.577 shares of Thermo Fisher Scientific common stock.
- Ms. Britt also acquired 5,338 stock options with an exercise price of $530.86 on February 19, 2025.
- These options become exercisable in four equal annual installments starting February 28, 2026, and expire on February 19, 2035.
- The filing also clarifies the vesting schedule for a performance-based restricted stock unit award granted on February 21, 2024, where the performance criteria were satisfied on February 19, 2025.
- One-third of these shares vest on February 28, 2025 and 2026, with the remaining one-third vesting on February 28, 2027, subject to adjustment based on long-term performance.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive suggests confidence, but it's a routine transaction.
Positives
- The acquisition of shares and stock options by a high-ranking executive could be interpreted as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule for the restricted stock units extends to February 28, 2027, with the final portion subject to adjustment based on the company's long-term performance relative to its peer group. The stock options vest in four equal annual installments beginning on February 28, 2026.
Industry Context
Executive stock ownership is a common practice in publicly traded companies like Thermo Fisher Scientific. These transactions are routinely disclosed to the SEC and provide insights into management's alignment with shareholder interests.
Stakeholder Impact
- The reported transactions may have a minor positive impact on shareholder sentiment, reflecting confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| February 21, 2024 | Date of the performance-based restricted stock unit award grant. |
| January 1, 2024 | Start date for the measurement period of the Company's total shareholder return compound annual growth rate (CAGR). |
| December 31, 2026 | End date for the measurement period of the Company's total shareholder return compound annual growth rate (CAGR). |
| February 19, 2025 | Date of the reported transactions: acquisition of common stock and stock options, and determination that performance criteria were satisfied. |
| February 21, 2025 | Date of the Form 4 filing. |
| February 28, 2025 | Date of the first vesting installment for one-third of the shares from the restricted stock unit award. |
| February 28, 2026 | Date of the second vesting installment for one-third of the shares from the restricted stock unit award and the start date for the vesting of the stock options. |
| February 28, 2027 | Date of the final vesting installment for one-third of the shares from the restricted stock unit award. |
| February 19, 2035 | Expiration date of the stock options. |
Keywords
Thermo Fisher Scientific, Lisa P. Britt, Form 4, Beneficial Ownership, Stock Options, Common Stock, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.